Wellington Management Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Wellington Management Group’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,813	Closed	-$334K	–	2232
2018 Q3	$334K	Buy	+4,813	New	+$365K	﹤0.01%	2119
2018 Q1	–	Sell	-15,767	Closed	-$842K	–	2343
2017 Q4	$842K	Sell	15,767 -19,478	-55%	-$1.08M	﹤0.01%	1933
2017 Q3	$2.1M	Hold	35,245	–	–	﹤0.01%	1709
2017 Q2	$2.78M	Buy	35,245 +30,348	+620%	+$2.48M	﹤0.01%	1612
2017 Q1	$406K	Buy	+4,897	New	+$364K	﹤0.01%	2109
2016 Q2	–	Sell	-18,700	Closed	-$757K	–	2201
2016 Q1	$757K	Sell	18,700 -11,917	-39%	-$756K	﹤0.01%	1869
2015 Q4	$2.71M	Buy	30,617 +4,367	+17%	+$345K	﹤0.01%	1543
2015 Q3	$1.94M	Buy	26,250 +20,950	+395%	+$1.74M	﹤0.01%	1638
2015 Q2	$429K	Buy	+5,300	New	+$345K	﹤0.01%	1988

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group's EGRX Position: Q4 2018 in Review

Wellington Management Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 4,813 shares — an estimated $334K sold.

Wellington Management Group first reported a position in EGRX in Q2 2015 and held it in 9 quarters. The position peaked at $2.78M in Q2 2017. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

Wellington Management Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Wellington Management Group sold 4,813 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $334K.
Wellington Management Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 9 quarters.
Wellington Management Group's Eagle Pharmaceuticals, Inc. position peaked at $2.78M in Q2 2017.
182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on Wellington Management Group's 13F filing for Q4 2018, filed 14 Feb 2019.